{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:09Z","timestamp":1761901389415,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.prro.2025.03.013","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:24:49Z","timestamp":1750433089000},"page":"e606-e616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Hypofractionated Radiation Therapy and Brachytherapy for Managing Prostate-Specific Membrane Antigen Positron Emission Tomography-Staged Organ-Confined Prostate Cancer: Primary Endpoint Analysis of a Prospective Study"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6229-5471","authenticated-orcid":false,"given":"Iosif","family":"Strouthos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstratios","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Antorkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiannis","family":"Roussakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantina","family":"Cloconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antria","family":"Savva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Christoforou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Vrachimis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Ferentinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.03.013_bib0001","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2025.03.013_bib0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0360-3016(02)03828-2","article-title":"How low is the alpha\/beta ratio for prostate cancer?","volume":"55","author":"Wang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.013_bib0003","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.013_bib0004","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0005","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group\/American College of Radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0006","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0007","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.prro.2025.03.013_bib0008","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2023.41.6_suppl.304","article-title":"10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016)","volume":"41","author":"Syndikus","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.prro.2025.03.013_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0010","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","article-title":"Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"23","author":"Sathya","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0011","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.013_bib0012","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.prro.2025.03.013_bib0013","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.03.013_bib0014","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0015","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: A radiation therapy oncology group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.013_bib0016","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1118\/1.597396","article-title":"ICRU report 50\u2014Prescribing, recording and reporting photon beam therapy","volume":"21","author":"Jones","year":"1994","journal-title":"Med Phys"},{"key":"10.1016\/j.prro.2025.03.013_bib0017","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0018","doi-asserted-by":"crossref","first-page":"01TR01","DOI":"10.1088\/1361-6560\/aaf26a","article-title":"The linear quadratic model: Usage, interpretation and challenges","volume":"64","author":"McMahon","year":"2018","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.prro.2025.03.013_bib0019","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0020","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.013_bib0021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","article-title":"What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation","volume":"115","author":"Zaorsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0022","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.radonc.2020.04.037","article-title":"Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials","volume":"148","author":"Lehrer","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0023","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijrobp.2017.05.013","article-title":"Long-term results of a randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"99","author":"Dayes","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.013_bib0024","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial","volume":"13","author":"Dearnaley","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.013_bib0026","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6_suppl","key":"10.1016\/j.prro.2025.03.013_bib0027","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2023.41.6_suppl.298","article-title":"PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)\u2014Primary endpoint analysis","volume":"41","author":"van As","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.prro.2025.03.013_bib0028","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2024.02.064","article-title":"A randomized trial comparing quality of life after low-dose rate or high-dose rate prostate brachytherapy boost with pelvic external beam radiation therapy","volume":"120","author":"Crook","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.013_bib0029","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2021.05.024","article-title":"Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life","volume":"161","author":"Musunuru","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.03.013_bib0030","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.brachy.2021.08.006","article-title":"Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer","volume":"20","author":"Gorovets","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.prro.2025.03.013_bib0031","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.brachy.2020.02.008","article-title":"A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated\/SBRT in the management of intermediate-risk prostate cancer","volume":"19","author":"Den","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.prro.2025.03.013_bib0032","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025001079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025001079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:44:06Z","timestamp":1761900246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025001079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1879850025001079"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.03.013","relation":{},"ISSN":["1879-8500"],"issn-type":[{"type":"print","value":"1879-8500"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Hypofractionated Radiation Therapy and Brachytherapy for Managing Prostate-Specific Membrane Antigen Positron Emission Tomography-Staged Organ-Confined Prostate Cancer: Primary Endpoint Analysis of a Prospective Study","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}